Stock Analiz

InfuSystem Holdings, Inc INFU

Medical/Dental Instruments · data as of November 13, 2026

$14.72Market cap $295M
Open the interactive analysis →

InfuSystem Holdings, Inc (INFU) is a healthcare company listed in the US with a market value of about $295M. In the twelve months to September 30, 2026 it had revenue of $144M and net income of $9M, a net margin of 6.5%.

Its overall Stock Analiz score is 2.6 out of 5 (average). The strongest part is financial health (5/5); the weakest is value (1/5).

Key numbers: a P/E of 33.5, a price to free cash flow of 11.9, 5-year revenue growth of 8% a year, a 5-year average ROIC of 5%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 42% below the current price.

About InfuSystem

InfuSystem is listed in the US and classified in medical/dental instruments. Revenue went from $71M in 2015 to $143M in 2025, growth of about 7.4% a year. It was profitable in 7 of the last 10 years in our data. Its share count fell by 2% over three years (buybacks).

Score: 2.6 / 5

Value1/5
Future growth2/5
Track record2/5
Financial health5/5
Shareholder returns3/5

Checks passed

  • P/FCF below 20
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year
  • 5-year revenue growth above 8% a year
  • Profitable 5 years in a row
  • More cash than debt, or low debt to equity
  • Positive free cash flow
  • Interest covered more than 5 times

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Strong R&D investment or growth above 20%
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)33.5
Forward P/E30.0
P/FCF11.9
P/S2.0
P/B4.6
EV/EBITDA11.4
PEG—
Dividend yield0.00%
FCF yield8.4%
Shareholder yield3.4%
Intrinsic value vs. price−42%

Growth and quality

Revenue growth (1 yr)6.4%
Revenue growth (5 yrs, per year)8.1%
EPS growth (5 yrs, per year)-17.3%
FCF growth (3 yrs, per year)13.0%
Net margin (5-yr avg.)1.7%
ROIC (5-yr avg.)4.6%
Profitable years (of last 10)7
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$144M$143M$135M$126M$110M$102M$97M$81M$67M$71M$70M
Net income$9M$7M$2M$872000$18000$1M$17M$1M-$1M-$21M-$222000
Free cash flow$25M$24M$19M$10M$17M$17M$19M$11M$11M$8M$8M
EPS (diluted)$0.44$0.31$0.11$0.04$0.00$0.06$0.80$0.07$-0.05$-0.91$-0.01
Net margin6.5%4.6%1.7%0.7%0.0%1.4%17.8%1.7%-1.6%-29.1%-0.3%
ROIC—9.1%6.2%3.6%1.5%2.6%8.3%4.7%0.6%-5.1%0.7%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 3 analysts is $18.50, 26% above the current price; targets range from $17.50 to $20.00; the consensus rating is “Strong buy”; expected EPS is $0.49 for the fiscal year ending December 31, 2026.

Frequently asked questions

What is InfuSystem’s P/E ratio?

About 33.5, based on the last twelve months of diluted earnings per share (forward P/E about 30.0).

Is InfuSystem stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 42% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does InfuSystem pay a dividend?

Not currently.

Is InfuSystem a good stock to buy?

We do not give buy or sell advice. InfuSystem scores 2.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.